|
| Press Releases |
|
 |
|
| Friday, March 27, 2026 |
|
|
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy |
| Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, announced today that an application for LENVIMA(R) (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, has been submitted in Japan for the additional dosage and administration in combination with WELIREG(R) (belzutifan), the first-in-class oral hypoxiainducible factor-2 alpha (HIF-2a) inhibitor from MSD, for the treatment of unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy. more info >> |
|
|
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency |
| Eisai Co., Ltd., a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, and Nuvation Bio Inc., a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) for taletrectinib for the treatment of advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). more info >> |
|
| Monday, March 23, 2026 |
|
|
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026 |
| Eisai Co., Ltd. and Biogen Inc. announced today that new real‑world findings from an analysis of long‑term treatment persistence and baseline characteristics among people receiving intravenous (IV) lecanemab (generic name, brand name LEQEMBI?), an anti‑amyloid‑β (Aβ) protofibril antibody, showed that most patients continue with ongoing lecanemab therapy after the initial 18 months of treatment. more info >> |
|
| Thursday, March 19, 2026 |
|
|
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide) |
| Eisai Co., Ltd. announced today that the administration of the anticancer agent EZH2 inhibitor "Tazverik(R) Tablets 200 mg" (generic name: tazemetostat hydrobromide), which is manufactured and marketed in Japan by Eisai should be discontinued. We plan to discontinue sales of this product once we have confirmed that it is no longer being administered to any patients. more info >> |
|
| Tuesday, March 17, 2026 |
|
|
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") has announced the establishment of Eisai Global Capability Centre (EGCC) within Eisai Knowledge Centre, India, in Visakhapatnam (Vizag), Andhra Pradesh, India. more info >> |
|
| Thursday, March 12, 2026 |
|
|
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it is launching an initiative to raise public awareness of the importance of sleep in collaboration with the smartphone application "Pokemon Sleep" more info >> |
|
|
エーザイ、『Pokemon Sleep』とのコラボレーションで眠りの大切さを広く伝える啓発活動を開始 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、スマートフォン向けアプリ『Pokémon Sleep』とのコラボレーションを通じて、眠りの大切さを広く伝える啓発活動に取り組むことをお知らせします。 more info >> |
|
| Wednesday, March 11, 2026 |
|
|
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting |
| Eisai Co., Ltd. announced today the company will present the latest findings on lecanemab, Eisai's anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease (AD), at the 20th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD(TM) 2026) from March 17-21, in Copenhagen, Denmark, and online. more info >> |
|
|
エーザイ、アルツハイマー・パーキンソン病学会（AD/PD 2026）において、レカネマブの長期実臨床治療をはじめとするアルツハイマー病の最新知見を発表 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫、以下エーザイ）は、2026 年 3 月17 日から 21 日にかけてデンマーク コペンハーゲンおよびバーチャルで開催される第 20 回アルツハイマー病・パーキンソン病学会（International Conference on Alzheimer's and Parkinson's Diseasesand related neurological disorders：AD/PD™ 2026）において、抗アミロイド β（Aβ）プロトフィブリル抗体レカネマブ（一般名、製品名「レケンビ®」）を含む、当社のアルツハイマー病（AD）領域の研究成果として、3 件の口頭発表を含む６件の発表を行うとともに、1 件のシンポジウムを主催することをお知らせします。 more info >> |
|
| Monday, March 2, 2026 |
|
|
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC) |
| Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada) and Eisai (Headquarters: Tokyo, CEO: Haruo Naito) today announced the first presentation of results from the Phase 3 LITESPARK-011 trial evaluating the dual oral regimen of WELIREG(R) (belzutifan), Merck & Co., Inc., Rahway, NJ, USA's first-in-class oral hypoxiainducible factor-2 alpha (HIF-2a) inhibitor, plus LENVIMA(R) (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of patients with advanced renal cell carcinoma (RCC) whose disease progressed on or after treatment with anti-programmed death receptor-1 (PD-1)/ programmed death-ligand 1 (PD-L1) therapy. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
美國馬球協會（USPA）與ESPN攜手呈現標誌性的USPA金杯賽，賽事將在USPA國家馬球中心舉行，由傳奇解說員克裡斯·福勒擔任主持
Apr 7, 2026 19:00 HKT/SGT
|
|
|
美国马球协会（USPA）与ESPN携手呈现标志性的USPA金杯赛，赛事将在USPA国家马球中心举行，由传奇解说员克里斯·福勒担任主持
Apr 7, 2026 19:00 HKT/SGT
|
|
|
U.S. Polo Assn. and ESPN Champion the Iconic USPA Gold Cup at the USPA National Polo Center, Hosted by Legendary Commentator Chris Fowler
Apr 7, 2026 19:00 HKT/SGT
|
|
|
Dwbrobot Launches Zero-Investment Robot Model to Accelerate Industrial Automation
Apr 7, 2026 18:00: JST
|
|
|
Dwbrobot Launches Zero-Investment Robot Model to Accelerate Industrial Automation
Apr 7, 2026 16:30 HKT/SGT
|
|
|
MHI Receives Contract for Renewal of APM System ATL SkyTrain at Hartsfield-Jackson Atlanta International Airport
Apr 7, 2026 16:42 JST
|
|
|
Datavault AI CEO Nathaniel T. Bradley to Deliver Flagship Keynotes on Breakthrough RWA Tokenization at CONV3RGENCE London and AssetRush x Zurich 2026
Apr 7, 2026 11:06 HKT/SGT
|
|
|
Datavault AI 執行長納撒尼爾·T·布拉德利將於 CONV3RGENCE London 及 AssetRush × Zurich 2026 大會發表關於 RWA 代幣化突破性進展的旗艦主題演講
Apr 6, 2026 22:00 HKT/SGT
|
|
|
Datavault AI 首席执行官内森尼尔·T·布拉德利将在 CONV3RGENCE 伦敦峰会及 AssetRush × 苏黎世 2026 峰会上发表关于 RWA 代币化突破性进展的主题演讲
Apr 6, 2026 22:00 HKT/SGT
|
|
|
Honda、「N-BOX」が2025年度 新車販売台数 第1位を獲得
Apr 6, 2026 16:00: JST
|
|
|
JFEと三菱商事、京浜扇島地区における電力事業とデータセンター事業を一体とした共同事業について基本合意書締結
Apr 6, 2026 15:30: JST
|
|
|
JFE Holdings and Mitsubishi Corporation Sign Second MOU to Advance Integrated Power and Data Center Project in Ohgishima, Keihin District
Apr 6, 2026 14:27 JST
|
|
|
The Full Spectrum of K-Culture in One Place: "2026 MyK FESTA" to Open June 25
Apr 3, 2026 23:00: JST
|
|
|
The Full Spectrum of K-Culture in One Place: "2026 MyK FESTA" to Open June 25
Apr 3, 2026 23:00 HKT/SGT
|
|
|
海通恒信2025年報：協同效應加速釋放 新興賽道引領結構升級
Apr 3, 2026 20:28 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
